Duke Abstracts Accepted For Presentation At 2018 GU ASCO Symposium

The Duke Prostate & Urologic Cancer Center has nine abstracts accepted for presentation at the 2018 Genitourinary Cancers (GU) Symposium of the American Society of Clinical Oncology (ASCO) taking place Tuesday, Feb. 8 through Saturday, Feb. 10 in San Francisco, California.

Held annually, researchers throughout the world gather for a three-day scientific retreat to discover and share groundbreaking research in genitourinary malignancies. Over the course of the symposium, attendees will engage in educational sessions, keynote lectures, oral abstract presentations and poster sessions highlighting the latest, breakthrough science in prostate and urologic cancers.

“We are pleased to showcase our data at this year’s GU ASCO symposium, and be a part of the cutting-edge research and paradigm shifts in clinical care for prostate and urologic cancers,” said Daniel George, MD, director of genitourinary oncology at Duke Cancer Institute. “Andrew Armstrong, MD, will be presenting on the treatment of prostate cancer with Radium-223, and the genomic and phenotypic evidence for prostate cancer osteomimicry in circulating tumor cells. We are committed to advancing our knowledge and moving science forward; GU ASCO is a great platform to further research collaborations with peers in academics and private industry.”

Duke Prostate & Urologic Cancer GU ASCO Abstracts:

1. CABOSUN Trial: Cabozantinib versus sunitinib for previously untreated patients with advanced renal cell carcinoma of intermediate or poor risk: subgroup analysis of progression-free survival and objective response rate in the Alliance A031203 CABOSUN trial.
   AUTHOR: Daniel J. George, MD
2. Exploratory Pharmacogenomic Analysis: Phase III Trial of Adjuvant Sunitinib in Patients With High-Risk Renal Cell Carcinoma.
   AUTHOR: Daniel J. George, MD
3. S-TRAC Trial: Sensitivity Analyses of Disease-Free Survival
   AUTHOR: Daniel J. George, MD
4. Clinical utility of Foundation One tissue: Molecular profiling in men with metastatic prostate cancer
   AUTHOR: Jason Zhu, MD
5. Radium-223: Genomic and phenotypic evidence for prostate cancer osteomimicry in men with metastatic castration resistant prostate cancer (mCRPC) treated with radium-223
   AUTHOR: Andrew Armstrong, MD
6. AbiRT: Phase II trial of 6 months ADT/abiraterone acetate + prednisone (AAP) and definitive radiotherapy (AbiRT) for men with intermediate to high risk localized prostate cancer
   AUTHOR: Bridget Koontz, MD
7. Expression of immune checkpoints: On circulating tumor cells in men with metastatic prostate cancer (mPC)
   AUTHOR: Tian Zhang, MD
8. Radium Chart Review: Patterns of Progression in Bone and Soft Tissue Following Treatment with Ra-223 in Metastatic Castrate Resistant Prostate Cancer (mCRPC)
   AUTHOR: Megan McNamara, MD
9. Strive Study: Impact of enzalutamide (ENZA) vs. bicalutamide (BIC) on health-related quality of life (HRQoL) of patients (pts) with castration-resistant prostate cancer (CRPC
   AUTHOR: Andrew Armstrong, MD